Wire · opportunities
RWD's Impact on Clinical Trial Recruitment Costs
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 18 September 2026 · Fusion42 review
The FDA is promoting the use of real-world data (RWD) to improve drug trial design and shorten recruitment timelines by reducing reliance on inaccurate self-reported patient data.
This Wire brief sits within Fusion42's coverage of Biotech, and 1 source has reported it between 18 Sep 2026 and 24 Sep 2026.
◆ ◆ The Wire takeaway
You need to rethink how you screen patients by integrating real-world data to avoid costly recruitment errors and delays in clinical trials. The traditional reliance on patient recall risks enrolling unsuitable participants and could jeopardise your study’s safety and timeline.
◆ Coverage
1 source · first reported 18 Sep 2026 · latest 24 Sep 2026
◆ Related on Wire
◆ Topics